Cell-free DNA methylation patterns (cfDNA methylation)

Cell-free DNA (cfDNA) methylation patterns refer to the epigenetic modifications, specifically the addition of methyl groups to cytosine bases in CpG islands, found on DNA fragments circulating in blood and other bodily fluids. These patterns are released from cells during processes such as apoptosis or necrosis and carry a unique signature that reflects the tissue of origin and the physiological or pathological state of the source cell [PMID: 32245907, 34163012]. While cfDNA methylation is not a classical therapeutic target like a receptor or enzyme, it is a revolutionary diagnostic 'target' used in liquid biopsies for the early detection of various cancers and other systemic diseases [PMID: 32245907]. In oncological contexts, specific hypermethylation of tumor suppressor genes or global hypomethylation can be detected with high sensitivity, often preceding clinical symptoms. Drugs do not interact with these circulating patterns directly; however, the enzymes responsible for creating these patterns, such as DNA methyltransferases (DNMTs), are therapeutic targets for epigenetic therapies like Azacitidine [PMID: 28882000]. Analysts should view cfDNA methylation as a high-value biomarker platform for patient stratification, treatment monitoring, and early disease screening rather than a site for drug binding.

Other names

Circulating methylated DNAcfDNA methylation signaturesMethylated cell-free DNAEpigenetic liquid biopsy markers

Not applicable as a therapeutic target; serves as a diagnostic target for detection and monitoring.